Kaposi sarcoma (KS) lymph node involvement represents spread of human herpesvirus 8 (HHV-8/KSHV)-associated vascular neoplasm to the lymphatic system. Most commonly seen in HIV/AIDS patients (epidemic type); also occurs in transplant recipients (iatrogenic), elderly men from Mediterranean/Eastern Europe (classic), and endemic African type. Cutaneous lesions (purple-red papules, plaques, nodules) generally present simultaneously with or before lymphadenopathy. Histologically characterized by spindle cell proliferation, slit-like vascular spaces, erythrocyte extravasation, and HHV-8 LANA-1 positivity. On imaging, lymph nodes demonstrate intense enhancement — reflecting the rich vascular content of the vascular neoplasm. Common in HIV patients with CD4 count <200; regression expected with antiretroviral therapy.
Age Range
20-60
Peak Age
38
Gender
Male predominant
Prevalence
Uncommon
Kaposi sarcoma lymph node involvement begins with HHV-8 (KSHV) infecting lymphatic endothelial cells. HHV-8 viral oncoproteins (vFLIP, vCyclin, LANA) increase cell proliferation and inhibit apoptosis pathways. The virus also encodes VEGF and angiopoietin homologs, triggering intense neoangiogenesis. This vascular proliferation creates the histological appearance characterized by slit-like vascular spaces formed by spindle cells. Extravasation of erythrocytes into these slit spaces causes hemosiderin deposition and clinically purple discoloration. On imaging, intense enhancement results from contrast agent accumulation in this rich neovascular network. Immunosuppression (CD4 decline with HIV or post-transplant) triggers disease by reducing T-cell responses controlling HHV-8 replication. T2 hyperintensity reflects the high water content of vascular spaces and perivascular edema. Diffusion restriction on DWI relates to increased tumoral cell density.
In the setting of HIV/AIDS or immunosuppression, the combination of intensely homogeneously enhancing generalized lymphadenopathy with concurrent cutaneous purple-red lesions is pathognomonic for Kaposi sarcoma. This clinico-radiological correlation strongly supports the diagnosis.
On B-mode ultrasonography, enlarged lymph nodes appear homogeneously hypoechoic. Hilum is generally lost or significantly compressed. Nodes may be oval or round. Internal structure is generally homogeneous and cystic necrosis is not expected. Enlarged nodes may be seen at multiple stations.
Report Sentence
On US, multiple enlarged, homogeneously hypoechoic lymph nodes with loss of hilum are noted at multiple stations; Kaposi sarcoma nodal involvement should be considered in the HIV/immunosuppression context.
On color Doppler, markedly increased vascularity is observed in enlarged lymph nodes — mixed vascularity pattern showing both hilar and peripheral distribution. Degree of vascularity reflects the intense neovascularity of the tumor. Low resistance index (RI <0.7) on spectral Doppler indicates increased vascular flow.
Report Sentence
Doppler ultrasonography demonstrates markedly increased mixed vascularity in enlarged lymph nodes, consistent with vascular neoplasm (Kaposi sarcoma).
On contrast-enhanced CT, enlarged lymph nodes demonstrate intense homogeneous enhancement — reflecting the rich vascular content of the vascular neoplasm. Enhancement degree may be more intense than reactive LAP or lymphoma. Necrosis is generally not seen (except in advanced stage disease). Nodes are generally well-defined. Concurrent cutaneous and visceral involvement (lung, GI, liver) may be detected on CT. Pleural effusion may accompany.
Report Sentence
Contrast-enhanced CT demonstrates enlarged, intensely homogeneously enhancing lymph nodes without necrosis at multiple stations; Kaposi sarcoma nodal involvement should be primarily considered in the HIV/immunosuppression context.
On DWI, enlarged lymph nodes demonstrate moderate to significant diffusion restriction. ADC values are generally in the range of 0.8-1.2 × 10⁻³ mm²/s. This restriction reflects the dense proliferation of spindle cells and narrow interstitial space between vascular channels.
Report Sentence
On DWI, moderate diffusion restriction is noted in enlarged lymph nodes (ADC: ___×10⁻³ mm²/s), consistent with vascular neoplasm.
On FDG PET-CT, Kaposi sarcoma-involved lymph nodes demonstrate intense FDG uptake (SUVmax generally 5-15). Uptake may show generalized distribution — concurrent involvement at cervical, axillary, mediastinal, retroperitoneal, inguinal stations. Concurrent cutaneous, pulmonary, and GI lesions may also be seen as FDG-avid. PET-CT plays a critical role in assessing disease extent and monitoring treatment response.
Report Sentence
FDG PET-CT demonstrates intense FDG uptake (SUVmax: ___) in enlarged lymph nodes at multiple stations; consistent with Kaposi sarcoma involvement in the HIV/immunosuppression context.
On T2-weighted images, enlarged lymph nodes demonstrate mild to moderate hyperintense signal. Signal is generally homogeneous. Vascular flow void areas may be seen in large nodes. May be isointense to mildly hyperintense on T1 (depending on hemosiderin or protein content).
Report Sentence
On MRI, enlarged lymph nodes demonstrate mild to moderate hyperintense homogeneous signal on T2; findings consistent with vascular neoplasm (Kaposi sarcoma).
Criteria
Seen in HIV/AIDS patients, especially those with CD4 <200. Most aggressive form. Widespread cutaneous, nodal, and visceral involvement. Regression expected with ART.
Distinct Features
Generalized lymphadenopathy, multiple organ involvement (lung, GI, liver), pleural effusion may accompany. Widespread intense uptake on PET-CT. Dramatic response to ART possible.
Criteria
In elderly men (60-80 years) of Mediterranean, Eastern European, Middle Eastern origin. Slow course. Skin involvement predominant in lower extremities. Nodal involvement more limited.
Distinct Features
Nodal involvement generally limited and indolent. Inguinal nodes most commonly involved station. Visceral involvement rare. May have 10+ years progression-free course.
Criteria
Develops in organ transplant recipients related to immunosuppressive therapy. May appear months to years after transplantation. Regression may occur with reduction of immunosuppression.
Distinct Features
Reduction of immunosuppression is first treatment option — balanced approach required with graft rejection risk. Nodal involvement variable. mTOR inhibitors (sirolimus) show both immunosuppression and anti-KS effects.
Distinguishing Feature
In HIV-associated NHL, enlarged nodes may show heterogeneous enhancement and central necrosis; in KS enhancement is more intense and homogeneous. NHL more commonly shows single dominant mass or conglomerate structure, while KS has multiple well-defined nodes predominant. Clinically, cutaneous purple lesions in KS are distinguishing.
Distinguishing Feature
In HIV-associated TB lymphadenitis, rim enhancement and central necrosis predominate; in KS, homogeneous intense enhancement predominates. TB typically concentrates in cervical and mediastinal stations, while KS shows more generalized distribution. Pulmonary involvement (miliary pattern, cavitary) accompanies TB.
Distinguishing Feature
Castleman disease (especially multicentric, HHV-8 associated form) may coexist with KS — both diseases are HHV-8 related. In Castleman nodes show very intense hypervascular enhancement (similar to KS); differentiation is usually by biopsy. IL-6 elevation and systemic symptoms are more prominent in Castleman.
Distinguishing Feature
In HIV-associated reactive (persistent generalized) LAP, nodes show mild to moderate enhancement and hilum is generally preserved; in KS enhancement is much more intense and hilum is generally lost. Cutaneous purple lesions do not accompany reactive LAP.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
3-monthKaposi sarcoma lymph node involvement requires management of underlying immunosuppression. In HIV/AIDS patients, initiation or optimization of antiretroviral therapy (ART) is first-line treatment — dramatic regression may be seen with CD4 recovery. In cases of widespread visceral involvement or rapid progression, chemotherapy (liposomal doxorubicin, paclitaxel) may be added. In transplant recipients, reduction of immunosuppression and switch to mTOR inhibitor is considered. Diagnosis is confirmed by excisional or core biopsy — HHV-8 LANA-1 immunohistochemistry is pathognomonic. Disease extent and treatment response are monitored with PET-CT. Prognosis is much better than pre-ART era.
Treatment of Kaposi sarcoma depends on HIV status and disease extent. In HIV-associated form, tumor regression may occur with antiretroviral therapy (HAART). Advanced cases may require chemotherapy (liposomal doxorubicin, paclitaxel) or immunotherapy. In transplant-associated form, reduction of immunosuppression is the first step.